Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

05:08
06/12/19
06/12
05:08
06/12/19
05:08

Genentech says Rituxan granted Priority Review by FDA

Genentech, a member of the Roche Group, announced that the FDA has accepted the company's supplemental Biologics License Application, or sBLA, and granted Priority Review for the use of Rituxan, in combination with glucocorticoids, or GCC, for the treatment of granulomatosis with polyangiitis, or GPA, and microscopic polyangiitis, or MPA, in children two years of age and older. GPA and MPA are rare, potentially life-threatening diseases affecting small and medium sized blood vessels.

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 20

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 04

    Nov

RHHBY Roche
$0.00

(0.00%)

05/23/19
RBCM
05/23/19
NO CHANGE
Target $143
RBCM
Outperform
RBC sees 'interesting parallels' between Intercept and Roche-acquired InterMune
RBC Capital analyst Brian Abrahams said in a new note to investors that he sees "a number of interesting parallels" between Intercept (ICPT) and InterMune, which he notes was acquired by Roche (RHHBY) for $8.3B in 2014. While he admits that "it is not a perfect apples-to-apples comparison," he highlights that both companies' lead drugs had tolerability questions and finite exclusivity periods and that competitive risks have been "overly hyped" for Intercept's obeticholic acid and InterMune's Esbriet. The analyst, who contends that the similarities "further highlight the significant valuation disconnect" for Intercept, keeps an Outperform rating and $143 price target on the shares.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $39
PIPR
Overweight
Roche approval has positive read through for MorphoSys, says Piper Jaffray
Roche's (RHHBY) accelerated approval of Polivy two months ahead of its FDA action date has a positive read through to MorphoSys' (MOR) MOR208, Piper Jaffray analyst Danielle Brill tells investors in a research note. While not a perfect comparison, the approval further signifies progression free survival data are not the most important efficacy measure for MOR208, adds the analyst. Further, she still thinks MOR208's efficacy and safety profile "appears distinctively better" than Polivy's. Brill remains confident for accelerated approval of MOR208 and believes that it could warrant a premium price-tag to Polivy's estimated average of $90,000 every four months. She reiterates an Overweight rating on MorphoSys shares with a $39 price target.
06/11/19
JANY
06/11/19
NO CHANGE
JANY
Buy
uniQure weakness a buying opportunity, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong said he does not see any fundamental reason for today's weakness in shares of uniQure (QURE), attributing the pullback as likely due to profit taking following some recent strong performance. Roche's (RHHBY) deal to buy Spark Therapeutics (ONCE) in February had a positive impact on the overall gene therapy sector and investor speculation has contributed to an over 30% increase in uniQure shares over the past two weeks, noted Zhong, who said his valuation does not include any acquisition assumption or premium. The analyst, who sees uniQure having the first FDA approval for an AAV gene therapy for hemophilia B and the first AAV gene therapy program in the clinic for Huntington's disease, keeps a Buy rating on the stock and would be a buyer amid today's weakness.

TODAY'S FREE FLY STORIES

MGA

Magna

$49.01

0.36 (0.74%)

08:41
06/27/19
06/27
08:41
06/27/19
08:41
Initiation
Magna initiated  »

Magna initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQBG

Sequential Brands

$0.50

-0.0049 (-0.98%)

08:41
06/27/19
06/27
08:41
06/27/19
08:41
Hot Stocks
Sequential Brands announces licensing agreement for Joe's brand »

Sequential Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPL

Texas Pacific Land Trust

$800.00

(0.00%)

08:41
06/27/19
06/27
08:41
06/27/19
08:41
Hot Stocks
Texas Pacific Land Trust comments on recent actions of dissident group »

Texas Pacific Land Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PES

Pioneer Energy

$0.28

0.0243 (9.48%)

08:40
06/27/19
06/27
08:40
06/27/19
08:40
Downgrade
Pioneer Energy rating change  »

Pioneer Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
06/27/19
06/27
08:40
06/27/19
08:40
General news
U.S. Q1 GDP growth was left unrevised at the 3.1% clip in the second look »

U.S. Q1 GDP growth was…

08:40
06/27/19
06/27
08:40
06/27/19
08:40
General news
FX Action: The dollar »

FX Action: The dollar…

08:40
06/27/19
06/27
08:40
06/27/19
08:40
General news
U.S. initial jobless claims climbed 10k to 227k in the week ended June 22 »

U.S. initial jobless…

SJR

Shaw Communications

$20.33

-0.06 (-0.29%)

08:39
06/27/19
06/27
08:39
06/27/19
08:39
Earnings
Shaw Communications reports Q3 EPS C$0.44 vs. (C$0.20) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AXL

American Axle

$12.05

0.25 (2.12%)

08:39
06/27/19
06/27
08:39
06/27/19
08:39
Initiation
American Axle initiated  »

Credit Suisse bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$92.41

-0.78 (-0.84%)

08:38
06/27/19
06/27
08:38
06/27/19
08:38
Conference/Events
Breaking Conference/Events news story on Celgene »

FDA PDUFA Date for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 03

    Jul

  • 03

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

INVH

Invitation Homes

$26.44

-0.63 (-2.33%)

, AMH

American Homes 4 Rent

$23.96

-0.38 (-1.56%)

08:38
06/27/19
06/27
08:38
06/27/19
08:38
Recommendations
Invitation Homes, American Homes 4 Rent, Essex Property Trust, AvalonBay, Equity Residential, UDR, Inc. analyst commentary  »

Morgan Stanley raises…

INVH

Invitation Homes

$26.44

-0.63 (-2.33%)

AMH

American Homes 4 Rent

$23.96

-0.38 (-1.56%)

ESS

Essex Property Trust

$286.29

-5.76 (-1.97%)

AVB

AvalonBay

$199.93

-3 (-1.48%)

EQR

Equity Residential

$75.09

-1.22 (-1.60%)

UDR

UDR, Inc.

$44.13

-0.96 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 10

    Jul

  • 11

    Jul

  • 31

    Jul

PHUN

Phunware

$2.90

-0.39 (-11.85%)

08:38
06/27/19
06/27
08:38
06/27/19
08:38
Hot Stocks
Phunware enters partnership with Wave Financial Group »

Phunware announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:37
06/27/19
06/27
08:37
06/27/19
08:37
General news
Corporate Profits After-tax data reported »

Corporate Profits…

PAYS

Paysign

$12.04

-0.21 (-1.71%)

08:36
06/27/19
06/27
08:36
06/27/19
08:36
Hot Stocks
Paysign appoints Matt Lanford as Chief Product Officer »

Paysign announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$25.27

-0.07 (-0.28%)

08:36
06/27/19
06/27
08:36
06/27/19
08:36
Hot Stocks
Rent-A-Center announces plan to initiate 25c per share quarterly dividend »

Rent-A-Center announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNE

Veoneer

$17.37

-0.065 (-0.37%)

08:36
06/27/19
06/27
08:36
06/27/19
08:36
Initiation
Veoneer initiated  »

Veoneer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

RNG

RingCentral

$110.98

-0.185 (-0.17%)

08:35
06/27/19
06/27
08:35
06/27/19
08:35
Recommendations
RingCentral analyst commentary  »

RingCentral added as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PFSW

PFSweb

$3.70

-0.1 (-2.63%)

08:35
06/27/19
06/27
08:35
06/27/19
08:35
Hot Stocks
PFSweb engaged by Shiseido Americas to provide order fulfillment »

PFSweb has been engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

GES

Guess

$15.22

0.51 (3.47%)

, AEO

American Eagle

$16.98

-0.19 (-1.11%)

08:35
06/27/19
06/27
08:35
06/27/19
08:35
Recommendations
Guess, American Eagle analyst commentary  »

Jefferies reiterates Buys…

GES

Guess

$15.22

0.51 (3.47%)

AEO

American Eagle

$16.98

-0.19 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$43.00

-0.78 (-1.78%)

08:34
06/27/19
06/27
08:34
06/27/19
08:34
Hot Stocks
Zenith announces dosing of first patient in Phase 1b/2 trial with Pfizer »

Zenith Epigenetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 28

    Aug

  • 16

    Sep

DRRX

Durect

$0.70

0.0295 (4.40%)

08:33
06/27/19
06/27
08:33
06/27/19
08:33
Hot Stocks
Durect submits response to FDA's Complete Response Letter for Posimir »

Durect has submitted a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:33
06/27/19
06/27
08:33
06/27/19
08:33
General news
Jobless Claims data reported »

Week of 6/22 Jobless…

CPS

Cooper-Standard

$44.63

1.43 (3.31%)

08:33
06/27/19
06/27
08:33
06/27/19
08:33
Hot Stocks
Cooper-Standard names Aleksandra Miziolek as chief transformation officer »

Cooper Standard announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.90

0.06 (0.61%)

08:33
06/27/19
06/27
08:33
06/27/19
08:33
Initiation
Ford initiated  »

Credit Suisse bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jul

  • 24

    Jul

  • 23

    Oct

EVOK

Evoke Pharma

$0.53

-0.0325 (-5.74%)

08:32
06/27/19
06/27
08:32
06/27/19
08:32
Hot Stocks
Evoke Pharma request Type A FDA meeting for resubmission of Gimoti NDA »

Evoke Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.